Hitaxa Fast (Desloratadine)

Hitaxa Fast is indicated for the symptomatic treatment of allergic conditions that respond to H1‑receptor antagonism. It is commonly employed in clinical practice for the following purposes:

• Relief of seasonal and perennial allergic rhinitis symptoms such as sneezing, nasal congestion, and itchy eyes.
• Management of chronic idiopathic urticaria to reduce wheal formation and itching.
• Adjunct therapy for allergic conjunctivitis when oral antihistamine control is needed.
• Supportive treatment of other histamine‑mediated allergic reactions under physician guidance.
• Use in patients who require a non‑sedating antihistamine option.

• Desloratadine, the active component of Hitaxa Fast, acts as a selective peripheral H1‑receptor antagonist. By binding competitively to H1 receptors on mast cells, basophils, and other target tissues, it blocks the action of endogenous histamine released during allergic responses. This inhibition prevents the cascade of intracellular events that lead to vasodilation, increased vascular permeability, and sensory nerve activation, thereby reducing typical allergy symptoms without significant central nervous system penetration.

Side effects associated with Hitaxa Fast are generally mild but can vary in frequency and severity.

Common

• Headache
• Dry mouth
• Fatigue or mild drowsiness
• Nausea or abdominal discomfort
• Mild insomnia

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing
• Cardiac arrhythmias (rare)
• Hepatic enzyme elevations
• Persistent tachycardia
• Severe skin reactions such as Stevens‑Johnson syndrome

Before using Hitaxa Fast, consider the following precautions to ensure safe and effective therapy:

• Assess liver function, as desloratadine is metabolized hepatically; dose adjustment may be needed in hepatic impairment.
• Evaluate renal function, especially in elderly patients, because renal excretion contributes to clearance.
• Use cautiously in patients with a history of cardiac arrhythmias or prolonged QT interval.
• Discuss pregnancy or breastfeeding status with a healthcare professional, as safety data are limited.
• Monitor for signs of hypersensitivity, particularly after the first dose.
• Avoid concurrent use with other sedating antihistamines to minimize additive central effects.

Hitaxa Fast may interact with other medicines, altering its efficacy or safety profile.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that can increase desloratadine plasma levels.
• Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) which may affect metabolism.
• Monoamine oxidase inhibitors (MAOIs) due to potential additive effects on the central nervous system.

Use with caution

• Alcohol, which can enhance sedation in susceptible individuals.
• Other antihistamines or anticholinergic agents, increasing risk of anticholinergic burden.
• Antifungal agents like itraconazole, which may modestly raise desloratadine concentrations.
• Medications that prolong QT interval, requiring cardiac monitoring.